ИСТИНА

• Охват: Международная
• Даты проведения: 8-10 июня 2015
• Место проведения: Lausanne, Switzerland
• Организатор:
  CHUV University of Lausanne, Switzerland
• Число участников: 122
• Число иностранных участников: 119
• Число участников из МГУ: 3
• Число докладчиков: 1
• Веб-сайт: http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=186&Itemid=345
• Описание конференции:

  Commercial protein drugs, which include recombinant monoclonal antibodies, subunit vaccines, immune modulators, and human enzymes, will likely exceed $100billion in market size within the next two years. A component of this extraordinary growth is the availability of new technologies to speed the time to market of new biologics, and to create improved versions of existing drugs. Among the new developments is the emerging use of green plants for recombinant protein production due to advantages over yeast, cultured mammalian or insect cells, or other living systems. It is becoming increasingly evident that: Government regulatory agencies have accepted plant production in new drug approval and licensure Monoclonal antibody production in plants offers rapid production advantages in comparison to mammalian cells, with at least equivalent product safety, purity and potency Metabolic engineering of tobacco as a host for protein production is advancing rapidly to allow highly uniform drug products, including post-translational modifications similar to those of human cells Plant-based manufacturing platforms hold major promise for next generation biogenerics (or biobetters with improved pharmacokinetic properties) Plant-made subunit vaccines are in the pipeline for multiple infectious diseases Ongoing corporate drug development at commercial scale is providing data to accurately determine the potential to reduce manufacturing cost of protein drugs under cGMP requirements using plant protein expression as the starting point PBVAB 2015 is the sixth meeting in this important and successful series. PBVAB 2015 will offer an international forum to review the current state of research in plant protein expression systems, down-stream processing technology, the pipeline of products now in development (including vaccines, monoclonal antibodies, and human enzymes), and efforts in using these technologies in areas beyond human health (including disease prevention in animals and aquaculture). PBVAB 2015 will aim to attract an international audience of researchers, clinicians, and representatives for academia, industry and government/regulatory/public health organizations. Representatives for the human, veterinary, plant communities with an interest in vaccinology, immunology, biotechnology issues in relation to plant-based systems will find PBVAB 2015 of value. PBVAB 2015 will seek to develop the synergy between the human and veterinary medical/immunological/plant biotechnology communities by focusing on the immunology, vaccinology, delivery, adjuvants, and efficacy of plant based proteins. PBVAB 2015 will aim to emphasise the take-off of the commercialisation of plant-based biologic products, the requirement for more academic based research to respond to the question: Where is the pipeline of products going to come from and what have we learned on the decision-making processes for that product pipeline?

• Добавил в систему: Иванов Петр Алексеевич

Доклады:

• 2015 Towards plant-derived universal Influenza vaccines: conserved antigens and rigid helical carriers (Стендовый)
• Авторы: Ivanov P., Petukhova N., Gasanova T.